Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

ALLMED LABORATORIES

Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx3product presentations
G1generic molecules
DF1dosage-form groups
TA0therapeutic areas
PKR3current price records
REG3registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage100%
products with at least one like-for-like comparator
Portfolio intelligence

Therapeutic mix

Unclassified3 products · 100%
Formulation footprint

Dosage forms

Capsule3 products
Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median3100% of comparable products
Near market median0within ±5% of median
Above market median00% of comparable products
Lowest-price equivalents1ties included
Company median price position -18.1% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Regulatory & price activity

Observed database signals

Registration numbers3
Price-history records3
Products with price history0
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date1 Jul 2025
Latest source observation9 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

3 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Bioral Ciclosporin 50 mg Capsule 50's 039852 PKR 6,023.38 PKR 120.47/capsule 20% below median
Bioral Ciclosporin 25 mg Capsule 50's 039851 PKR 3,010.91 PKR 60.22/capsule 18% below median
Bioral Ciclosporin 100 mg Capsule 50's 039853 PKR 12,037.45 PKR 240.75/capsule 18% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.